Part B Drugs At Home: Medicare Policy Responds To COVID-Driven Access Concerns
Executive Summary
Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.
You may also be interested in...
Medicare Pressed To Expand Home Infusion Emergency Access Plan Even Further
Plan to allow broader coverage for home infused drugs during the COVID-19 emergency prompts opposition from providers seeking an approach more in line with commercial insurance practices.
Medicare Will Boost Physician Reimbursement For Sharing COVID-19 Clinical Trial Data
Participants in CMS's Quality Payment Program can earn credit to boost their Medicare reimbursements by reporting information from COVID-19 drug trials through a clinical trial repository or registry; NIH issues treatment guidelines for the coronavirus that are to be continuously updated.
Drug Coverage In The Pandemic: US Payers Shift Focus From Costs To Access, For Now
Payer concessions to ensure access to drugs during the COVID-19 outbreak offer a benefit to patients and biopharma. But the costs involved could intensify future efforts to manage drug spending.